Literature DB >> 27378242

EYA4 functions as tumor suppressor gene and prognostic marker in pancreatic ductal adenocarcinoma through β-catenin/ID2 pathway.

Shi-Jing Mo1, Xin Liu1, Xiao-Yi Hao1, Wei Chen1, Kun-Song Zhang1, Jian-Peng Cai1, Jia-Ming Lai1, Li-Jian Liang1, Xiao-Yu Yin2.   

Abstract

Eye absent homolog 4 (EYA4) was initially found as key gene in controlling eye development in Drosophila. We recently found that EYA4 was an independent prognostic factor in hepatocellular carcinoma. Its biological functions in malignancies remained unknown. The present study aimed at investigating its biological functions, molecular mechanisms and prognostic values in pancreatic ductal adenocarcinoma (PDAC). Overexpression of EYA4 in PDAC cells inhibited proliferation and invasion in vitro and tumor growth in vivo. Depletion of EYA4 in PDAC cells enhanced proliferation and invasion in vitro and tumor growth in vivo. Mechanistically, armed with the serine/threonine-specific protein phosphatase activity, EYA4 dephosphorylated β-catenin at Ser675, blocked β-catenin nuclear translocation and inhibited ID2 transactivation. Consistently, EYA4 expression inversely correlated with the levels of p-Ser675-β-catenin and ID2 in tissues. EYA4 expression in PDAC tissues was significantly reduced as compared with adjacent non-tumoral tissues. EYA4 expression was an independent prognostic factor in PDAC, with a lower EYA4 level in association with shorter long-term survival and disease-free time. We showed that EYA4 functioned as tumor suppressor gene in PDAC via repressing β-catenin/ID2 activation, and was an independent prognostic factor in PDAC.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  EYA4; Pancreatic ductal adenocarcinoma; Prognostic marker; Tumor suppresser gene; β-catenin/ID2 pathway

Mesh:

Substances:

Year:  2016        PMID: 27378242     DOI: 10.1016/j.canlet.2016.06.021

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  12 in total

1.  Peroxiredoxin 4 suppresses anoikis and augments growth and metastasis of hepatocellular carcinoma cells through the β-catenin/ID2 pathway.

Authors:  Wei Wang; Xia-Bo Shen; Da-Bing Huang; Wei Jia; Wen-Bin Liu; Yi-Fu He
Journal:  Cell Oncol (Dordr)       Date:  2019-06-29       Impact factor: 6.730

2.  Gene expression profiling informs HPV cervical histopathology but not recurrence/relapse after LEEP in ART-suppressed HIV+HPV+ women.

Authors:  Emmanouil Papasavvas; Andrew V Kossenkov; Livio Azzoni; Nicola M Zetola; Agnieszka Mackiewicz; Brian N Ross; Matthew Fair; Surya Vadrevu; Doreen Ramogola-Masire; Ian Sanne; Cynthia Firnhaber; Luis J Montaner
Journal:  Carcinogenesis       Date:  2019-04-29       Impact factor: 4.944

3.  Aberrant methylation of EYA4 promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma.

Authors:  Mei Luo; Yuan Li; Xuejiao Shi; Wenhui Yang; Fang Zhou; Nan Sun; Jie He
Journal:  Cancer Sci       Date:  2018-05-26       Impact factor: 6.716

4.  RDGN-based predictive model for the prognosis of breast cancer.

Authors:  Bing Dong; Ming Yi; Suxia Luo; Anping Li; Kongming Wu
Journal:  Exp Hematol Oncol       Date:  2020-06-15

5.  Circular RNA ACVR2A suppresses bladder cancer cells proliferation and metastasis through miR-626/EYA4 axis.

Authors:  Wei Dong; Junming Bi; Hongwei Liu; Dong Yan; Qingqing He; Qianghua Zhou; Qiong Wang; Ruihui Xie; Yinjie Su; Meihua Yang; Tianxin Lin; Jian Huang
Journal:  Mol Cancer       Date:  2019-05-17       Impact factor: 27.401

6.  EYA4 serves as a prognostic biomarker in hepatocellular carcinoma and suppresses tumour angiogenesis and metastasis.

Authors:  Fangming Gu; Shengxian Yuan; Lei Liu; Peng Zhu; Yuan Yang; Zeya Pan; Weiping Zhou
Journal:  J Cell Mol Med       Date:  2019-04-07       Impact factor: 5.310

7.  MFAP5 facilitates the aggressiveness of intrahepatic Cholangiocarcinoma by activating the Notch1 signaling pathway.

Authors:  Jian-Hui Li; Xiao-Xu Zhu; Fu-Xi Li; Chen-Song Huang; Xi-Tai Huang; Jie-Qin Wang; Zhuo-Xing Gao; Shi-Jin Li; Qiong-Cong Xu; Wei Zhao; Xiao-Yu Yin
Journal:  J Exp Clin Cancer Res       Date:  2019-11-27

8.  Transcriptional downregulation of microRNA-19a by ROS production and NF-κB deactivation governs resistance to oxidative stress-initiated apoptosis.

Authors:  Jun Hong; Ying Wang; Bang-Chuan Hu; Liang Xu; Jing-Quan Liu; Min-Hua Chen; Jin-Zhu Wang; Fang Han; Yang Zheng; Xu Chen; Qian Li; Xiang-Hong Yang; Ren-Hua Sun; Shi-Jing Mo
Journal:  Oncotarget       Date:  2017-08-12

9.  EYA4 inhibits hepatocellular carcinoma growth and invasion by suppressing NF-κB-dependent RAP1 transactivation.

Authors:  Shi-Jing Mo; Xun Hou; Xiao-Yi Hao; Jian-Peng Cai; Xin Liu; Wei Chen; Dong Chen; Xiao-Yu Yin
Journal:  Cancer Commun (Lond)       Date:  2018-04-03

10.  EYA4 inhibits hepatocellular carcinoma by repressing MYCBP by dephosphorylating β-catenin at Ser552.

Authors:  Xiao-Xu Zhu; Jian-Hui Li; Jian-Peng Cai; Xun Hou; Chen-Song Huang; Xi-Tai Huang; Jie-Qin Wang; Shi-Jin Li; Qiong-Cong Xu; Xiao-Yu Yin
Journal:  Cancer Sci       Date:  2019-08-28       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.